What were the effects of candesartan on mortality and morbidity in patients with chronic heart failure?
The effects of candesartan on mortality and morbidity in patients with chronic heart failure were studied as part of the CHARM-Overall program. The results of the study, published in The Lancet in 2003, showed that patients taking candesartan had a significant reduction in mortality and morbidity compared to those taking enalapril. The study also found that candesartan had a greater effect on reducing mortality and morbidity than enalapril alone. Additionally, the study found that candesartan was more effective than enalapril at reducing the risk of stroke, hospitalization for heart failure, and hospitalization for any cause. These results support the use of candesartan in patients with chronic heart failure.  